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Abstract
Maximisation of the ratio of normal tissue preservation and tumour cell reduction is the main concept of radiotherapy
alone or combined with chemo-, immuno- or biologically targeted therapy. The foremost parameter influencing this
ratio is radiation sensitivity and its modulation towards a more efficient killing of tumour cells and a better
preservation of normal tissue at the same time is the overall aim of modern therapy schemas. Nevertheless, this
requires a deep understanding of the molecular mechanisms of radiation sensitivity in order to identify its key players
as potential therapeutic targets. Moreover, the success of conventional approaches that tried to statistically associate
altered radiation sensitivity with any molecular phenotype such as gene expression proofed to be somewhat limited
since the number of clinically used targets is rather sparse. However, currently a paradigm shift is taking place from
pure frequentistic association analysis to the rather holistic systems biology approach that seeks to mathematically
model the system to be investigated and to allow the prediction of an altered phenotype as the function of one
single or a signature of biomarkers. Integrative systems biology also considers the data from different molecular levels
such as the genome, transcriptome or proteome in order to partially or fully comprehend the causal chain of
molecular mechanisms. An example for the application of this concept currently carried out at the Clinical
Cooperation Group “Personalized Radiotherapy in Head and Neck Cancer” of the Helmholtz-Zentrum München and
the LMU Munich is described. This review article strives for providing a compact overview on the state of the art of
systems biology, its actual challenges, potential applications, chances and limitations in radiation oncology research
working towards improved personalised therapy concepts using this relatively new methodology.
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Introduction
Why we need to improve radiation therapy
Radiation therapy is beside chemo-/immunotherapy and
surgery part of the standard treatment of many cancers.
Worldwide approx. 13 million new cancer cases and approx.
7.6 million cancer-related deaths arise every year, about
half of them in the developed countries [1]. About 60% of
cancer cases [2] are treatable with radiotherapy - there-
fore, any improvement of the success of this treatment
option comes with a huge potential impact on the abso-
lute number of additionally cured patients. In the case of
head and neck squamous cell carcinoma (HNSCC), a
tumour entity that is - mostly in combination with chemo-
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or immunotherapy - predestinated for radiotherapy, the
overall 5-years survival rate is only 45-50% [3] while this
rather discouraging number is mostly attributable to the
high recurrence rate of this type of cancer which in turn is
caused by the resistance of tumour cells to the treatment.
Resistance in this context is of multifactorial nature and
the specific contributions of radiation alone and the con-
comitant treatments are challenging to be ruled out. How-
ever, it is obvious enough that improvement of radiation
therapy would have a significant positive impact on over-
all therapy success. Moreover, radiation resistance causing
local recurrence of the tumours [4] can be of intrinsic nature
and thereby a matter of predispositions carried by the
patient. The other option is that resistance to therapy is
acquired in the course of the therapy as a result of tumour
cell evolution during which some cells attain properties of
resistance against the pressures built during radiotherapy
i.e. reduced radiation sensitivity and which then allow
them to overgrow cells missing these properties. Hence,
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in the context of radiation therapy, individual radiation
sensitivity seems to be the key feature of tumours and its
understanding needs to be addressed when it comes to
efforts of improving the efficiency of radiotherapy.
Whilst a number of markers, although not having made
it into clinical practice, driving the radiation sensitivity
of normal tissue were identified [5], the knowledge on
radiation sensitivity associated markers and mechanisms
in tumour cells is sparse. But the overall prerequisite
for improving the long-term efficiency of raditoherapy is
a deep understanding of the underlying mechanisms of
radiation sensitivity in tumour cells in order to get a han-
dle on the control of this phenomenon. The approaches
that were taken so far and which were mostly based on
plain association testing have not revealed any clinically
applied key markers or targets for the modulation of
radiation sensitivity in radiation therapy, yet. This might
be due to the multifactorial nature of reduced radiation
sensitivity which is a mixture of stochastic and determin-
istic effects and most likely the result of intrinsic and
acquired alterations of the cells. Therefore, a rather holis-
tic approach that seeks to address this multifactoriality
instead of singling out particular factors for investigation
is promising to provide the potential of revealing mecha-
nisms and their key players to be targeted - therefore, sys-
tems biology approaches may provide the solution here.
Targeted treatment options combined with
radiation therapy
The phenomenon of radiation resistance is frequently
seen in tumours that were treated by radiation therapy or
concomitant radiation therapy. Although the mechanisms
governing radiation resistance are not fully understood
there are already some radiotherapy concomitant treat-
ment options that have made it into clinics that specif-
ically target important signalling pathways or the cells
surrounding the tumour that are known to have an impact
on the radiation sensitivity. A review by Kaliberov and
Buchsbaum [6] summarises the molecular mechanisms of
cellular response to radiation and which are involved in
the acquired generation of radiation resistance: base exci-
sion repair, non-homologous end joining or homologous
recombination of double-strand breaks or programmed
cell death. Another classification of target mechanisms
was formulated by Orth et al. [2] who distinguish radio-
therapy concomitant targeted treatment options that
modulate radiation sensitivity by aiming at theDNA dam-
age response, topoisomerases, the apoptosis network, cell
division, heat shock response, the EGFR pathway and the
tumour micro milieu. While all of those treatment targets
and the modulation of them aims at increasing the radia-
tion sensitivity of tumour cells are promising and already
partly successful in improving patients’ outcome a real
breakthrough was not achieved, yet.
Systems biology and its potential role in clinical
radiation research
As explained in the previous section existing treatment
options accompanying radiotherapy already improve
prognosis of the patients, new ways of identifying pow-
erful radiation sensitivity modulators have to be explored
and systems biology appear to be promising.
Definiton andmeaning of systems biology
The term systems biology is now widely used and there
is not one common definition of it. In reality, there
are uncountable ways of understanding, explaining and
applying systems biology. Concepts as represented in
review articles by Hornberg et al. [7] or Bruggeman and
Westerhoff [8] nicely describe what could be considered
as common understanding of systems biology. In order to
make clear how I understand systems biology I suggest
one definition of systems biology as follows:
While traditional, reductionistic approaches investi-
gated the property of one or of a few components (i.e.
molecules) or their interaction with one or a few other
molecules at the time, systems biology investigates the
emergent properties of the system under investigation
(e.g. organelles, cells, organs, organisms or eco systems)
when multiple entities interact in networks. To do so, sys-
tems biology requires highly interdisciplinary approaches
involving expertise from physics, mathematics, graph net-
work theory and biology that uses all molecular and other
data (such as phenotypic data or clinical data) available
for integration and the creation of a systems model that
is capable of predicting the response of the system to a
particular perturbation.
Systems biology for certain has its origin in physics,
a discipline that traditionally builds models of what is
observed in order to predict the “response” to a perturba-
tion. So it is for example possible to deduct from any cir-
cuit diagram of a system consisting of a battery, resistors
and LEDs what will happen when any of the included ele-
ments are changed in any way (perturbed). The accuracy
of the prediction in the case of circuit diagrams is very
good, almost perfect for smaller systems, but also very
good for highly complex systems. This very high level of
accuracy is because we know every single part making up
the system and we know how and in which way these ele-
ments are connected to each other. Of course, also here we
have to accept some inaccuracy, but compared to biolog-
ical systems technical systems are a almost perfect world.
In contrast to technical systems, the behaviour of biologi-
cal systems, such as cells, organs, tumours, organisms etc.
are not very much predictable. This might be due to two
reasons: firstly, compared to technical systems we do in
the moment not know enough about the elements biolog-
ical systems are composed of and most importantly we
do not know how these work together. Secondly, technical
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systems are usually composed in a modular fashion which
makes even very complex systems controllable and pre-
dictable. Whether biological systems are modular as well
or not cannot be answered in the moment. So is the “dis-
covery” of epigenetics and post-transcriptional regulation
by miRNAs not older than 20 years and we still miss THE
explanation for how biological systems and the elements
they are composed of really work together. However, there
seems to be a significant controversial between the think-
ing of biologists who have the genuine interest in using
systems biology approaches and those who actually have
the expertise of designing and applying these approaches.
The article “Can a biologist fix a radio?” by Lazebnik [9]
nicely describes this situation in an highly informative and
truly entertaining way.
Systems biology can be used to find the causal rela-
tionships between the elements making up a biological
system which are genes, mRNAs, miRNAs, proteins and
metabolites - between receptors, transcription factors and
phenotypic effects. With regard to the identification of all
of these elements we are certainly not far off completion,
however we need to understand how these work together.
And we are trying to do this by applying the methodolo-
gies from systems physics to biology. The main steps in
getting to a systemsmodel is to identify the network that is
affected by the perturbation, to reduce this network to the
highest informative elements and to model the response
of the network to the perturbation.
Finally, systems biology allows to think in processes
rather than in momentary snapshots reflected by single
measurements done at random time points. Provided the
required time-resolved data are availablemolecularmech-
anisms can be described as a function of time. Bechtel
[10] generalises this concept and assumes an organism
to be composed of oscillating processes and that disrup-
tion of these processes in fact leads to diseases. The other
way around this rather philosophic point of view in con-
sequence means that we have to identify the processes
and the elements they are composed of in order to come
to a solution that allows to ‘resynchronise’ the disrupted
oscillating processes.
Multi-level data integration
Integration of the data from the multiple molecular levels
is a subdiscipline of systems biology. Themain task of data
integration is to identify causal relationships between the
different molecular levels (Figure 1). From the resulting
data we can learn how the different levels work together
and what the causal relationship between a particular per-
turbation and the phenotype (e.g. radiation treatment of
cells and its impact on the survival rate of the cells) is.
The most common molecular levels being characterised
in molecular studies are the genome level by array CGH
or SNPmicroarray analysis [11,12], the transcriptome and
miRNA level by expression microarrays [13,14], global
methylation patterns by either hybridisation of methy-
lated sequences enriched by chromatin immunoprecipi-
tation (ChiP, [15]) onto microarrays (ChiP-on-chip [16])
or microarray-based characterisation of the genome-wide
methylation status after bisulfite-conversion of genomic
DNA [17]. Moreover proteomics methodology allows to
characterise the proteome, metabolome or lipidome [18].
One way of identifying causal relationships between dif-
ferent molecular levels is to bioinformatically match the
measurements from the levels to be integrated. Match-
ing of data at the genomic level can be achieved by
using the genomic location of the probes of each plat-
form - this applies for the integration of DNA methy-
lation profiles with array CGH profiles. If one wants to
find possible associations betweenmiRNA expression and
the genomic copy number, the location of the probes of
the miRNAs microarray need to be matched with that
from the genomic positions of the probes of the CGH
array ([19,20]). In the case of integration of gene expres-
sion with protein expression data the mRNA microar-
ray probes and protein expressions are matched using
the gene/protein names. Another extremely important
switches in the regulation of gene and protein expres-
sion are transcription factors that can be considered
as a feedback connection from the protein level to the
genomic level (Figure 1). In order to test possible asso-
ciations between transcription factors and protein/gene
expression, genes that are under control of a particu-
lar transcription factor need to be either experimentally
identified by Chip-seq technology [21] or by in silico anal-
ysis using algorithms predicting transcription-factor gene
relationships based on promoter-affinity analysis [22].
Other ways of integratingmulti-level data that not directly
match the elements of the different molecular layers is
based on graphical models or statistical associations. Two
major approaches representing these concepts are gaus-
sian graphical modelling [23] and genotype-environment
interaction analysis [24]. Gaussian graphical models are
based on partial correlation which assumes that the corre-
lation of two variables is influenced by a third variable. By
using this approach it is for example possible to identify
gene regulatory networks that are specifically influenced
by histone acetylation [25] or to integrate metabolomics
with genomics [26]. In the case of genotype-environment
interaction analysis the information from genomics, tran-
scriptomics and on the phenotype (e.g. disease) are inte-
grated in such a way that potential targets from the
expression level for modulating the phenotype can be
identified. Moreover, an important element of multi-
level integrative analysis is the use of a priori knowl-
edge on interactions using appropriate databases. There
is a number of databases and tools around allowing
not only pathway enrichment but also topology-based
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Figure 1 Integration of multiple omics-level. Simplified overview of the integration of omics data at the DNA, transcript and protein level and the
regulatory miRNA and DNA methylation levels. According to the “central dogma of molecular biology” [34] information is transferred from DNA
(genes, blue) to the RNA level (transcripts, green) and to the protein level (proteins, red) in a linear manner. Proteins i.e. enzymes then catalyse
biochemical reactions in which metabolites are processed. The metabolites are indicated by grey circles whilst the κ sign symbolises that this
process follows certain kinetics. The concentration of metabolites is well measured by receptor proteins - therefore, there is a strong
communication between the protein and metabolite level. However, both transcription and translation and the lifetime of transcripts and proteins
is regulated by other levels such as DNA methylation (cyan) [35,36] and miRNAs (pink) [37,38]. Mediated by transcription factors (yellow) [39,40]
there is also a powerful feedback from the protein level back to the DNA level. Another powerful molecular switch are proteins (DNA
methyltransferases and DNA demethylases, light-blue) that control transcription by changing the level of methylation of histones - therefore, there
is a feedback from the protein level to the DNA methylation level.
pathway analysis. The development and state of the art
of pathway analysis over the last decade from simple
gene set overrepresentation analysis over functional class
scoring (FCS) approaches to the lastest generation of
pathway topology based approaches is nicely reviewed
by Khatri et al. [27]. Examples for databases providing
protein-protein interactions are http://www.genome.jp/
kegg/KEGG [28] or http://www.reactome.orgReactome
[29] or http://string-db.orgSTRING [30]. These databases
provide interaction networks at a global level or allow
to specifically search for interactions of a candidate
of interest. If available the interactions or interaction
predictions are classified according to their level or
source of evidence (e.g. text-mining vs. evidence by two-
hybrid assays [31]). A very straightforward tool to match
genes of interest to existing knowledge of interaction
is the http://wiki.reactome.org/index.php/Reactome_FI_
Cytoscape_PluginReactome FI Cytoscape Plugin, a plugin
for http://www.cytoscape.orgCytoscape [32] that allows to
explore known or predicted interactions between genes
or proteins e.g. from a comparative gene expression study
and to nicely visualise the results in the form of an inter-
action network. An example for an Reactome FI analysis
with the genes revealed to be differentially expressed in
lymphocytes of HNSCC patients before and after thera-
peutic irradiation [33] is shown in Figure 2.
Network reconstruction
A lot of effort was put into the development and
application of network reconstruction approaches using
high-dimensional data for the delineation of molecular
interactions. The dimensionality of the dataset is deter-
mined by the number of measurements (e.g. the num-
ber of probes on a microarray) which is usually much
greater than the number of samples, the latter of which
determining the maximum rank in a covariance matrix -
the basis for many network reconstruction approaches.
The smaller the number of samples and consequently
the maximum rank, the lower the chance of finding true
molecular interactions. In order to address this prob-
lem Thomaz et al. suggested the MECS method (max-
imum entropy covariance selection) for the estimation
of covariance [41]. One very remarkable effort to sys-
tematically assess the performance of different network
reconstruction approaches in different data situations
(static measurements from clinical samples vs. dynamic
data from time-course perturbation experiments) was the
“Network Inference Challenge” of the DREAM (Dialogue
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Figure 2 Reactome FI functional interaction network generated using the differentially expressed genes from a study by Henriquez et al.
[33] comparing global microarray expression profiles of lymphocytes from patients before and after 2Gy X-ray irradiation. From the 66
HGNC annotated genes (Supplementary table two [33]) 44 were found to be part of an interaction network. So-called linkers (n=15) i.e. proteins not
part of the gene list that allow indirect interaction between two genes are indicated by diamond-shape nodes and the genes from the list by circles.
Predicted interactions are indicated by dashed black lines and interactions for which experimental evidence exists by solid black lines. Where known
the type of interaction is indicated by arrow-headed lines (activating) or by bar-headed lines (inactivating/inhibiting).
for Reverse Engineering Assessments and Methods) ini-
tiative. A summary of the approaches and the outcome of
this challenge was published in 2012 [42]. The reference
for assessing the performance of the methods were the
a priori known interaction network of S. cerevisiae along
with mRNA and protein expression data and a dataset
consisting of a simulated interaction network along with
mRNA array expression data. There are various methods
for the reconstruction of gene regulatory networks avail-
able and all of them have strengths and weaknesses and
to-date there is no one-for-all solution available that works
for every data situation. Every method and network that is
reconstructed comes with a certain level of uncertainty i.e.
false positive and false negative findings. A review article
by Karlebach and Shamir [43] gives an excellent and com-
prehensive overview on the various approaches available
and discusses the advantages and disadvantages of each
method.
Graph network theory and network visualisation
The reconstructed gene regulatory networks can be
described, visualised and analysed by the so-called graph
network theory, a method that is widely used, most
importantly in social sciences while social networks are
probably the most popular application of network graph
theory. Popular network visualisation tools are yED and
Cytoscape [32]. The overall principle of graph network
theory is to understand the elements (genes, proteins,
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metabolites etc.) making up a network as nodes or ver-
tices and the connections between them as edges and
to mathematically analyse the structure and topology of
these networks. Mitrea et al. wrote an excellent and easy
to understand review article on this [44]. An impor-
tant feature of graph network theory is the possibility
to analyse the “importance” of any given node or set of
nodes by considering the topology of the network they
are embedded in. Amongst the most commonly used
metrics for this are the so-called centrality measures
such as degree, betweenness, closeness, and eigenvector
centrality [45].
Mathematical modelling of “systems” networks
The overall objective of systems biology approaches is to
come to a mathematical model that allows to predict the
response of the cells to specific perturbations, for exam-
ple the treatment with a particular drug. The principle of
mathematical modelling is to use experimental measure-
ments on the expression of genes or (phospho-)proteins of
the nodes composing the network of investigation in order
to explain causal relationships between the perturbation
and response. In frame of this review it is not possible to
go into detail of the commonly used approaches of math-
ematical systems modelling. However, for this purpose I
recommend a review article by Klipp and Liebermeister
(2006) that gives a comprehensive overview on the topic
[46]. A very basic and central element in modelling gene
regulatory networks are so-called ODEs (ordinary differ-
ential equations) [47] that basically describe the change
of concentrations over time. The rates at which the con-
centrations change and the mode of kinetics need to be
individually chosen for the system to be modelled. The
prototype of an ODE being used in the reconstruction of
gene regulatory networks is the Hill differential equation
[48] that initially was built to describe kinetics of the
binding and dissociation of oxygen to haemoglobin. Gen-
eralisation of the Hill kinetics is frequently used in the
reconstruction of gene regulatory networks. Solving the
equation allows to come upwith a first predictionwhich in
turn has to be compared with real experimental measure-
ments followed by an iterative adjustment of the initial
model in order to come to a final model that allows most
accurate prediction of the behaviour of the network in
response to any perturbation.
Promising outcomes from two systems
biology studies
Two recent studies on colon cancer [49,50] that system-
atically modelled the response of the RAS/PI3K signalling
pathway to inhibition of EGFR by cetuximab revealed
strong negative feedback loops between ERK and EGFR.
This feedback loop immediately compensates any EGFR
inhibition by cetuximab by activating EGFR. Therefore,
only double-inhibition of EGFR and MEK [49] or BRAF
[50] seems to break this feedback connection in order to
bypass any acquired resistance to cetuximab. Actually, a
study on colon cancer is currently trialling a combinato-
rial treatment of BRAF/MEK and EGFR with Dabrafenib,
Trametinib and Panitumumab (www.clinicaltrials.gov, ID:
NCT01750918). Referring to the Klinger et al. study [49]
a systems model should not be of too high complexity
and should be therefore very much reduced to informative
nodes only.
These two studies could serve as a role model for tack-
ling the phenomenon of acquired resistance in HNSCC to
radiation treatment. The activities of the below described
clinical cooperation group are actually also aiming to
get to a systems model explaining acquired resistance to
radiotherapy in HNSCC and thereby providing molecular
targets to break resistance to therapy.
An example of an application of systems biology
in radiation oncology research: the clinical
cooperation group “Personalized radiotherapy
in head and neck cancer”
The clinical cooperation group (CCG) “Personalized
Radiotherapy in Head and Neck Cancer” is a struc-
ture aiming at the intimate collaboration of research and
oncology in order to understand the mechanisms of radi-
ation resistance in HNSCC and to identify targets that
allow to overcome resistance to radiation therapy. The
CCG allows intensive exchange of expertise and knowl-
edge between academic and oncology research whilst the
clinicians formulate the questions to be addressed by the
research carried out and thereby allow the researchers
to most efficiently work towards the common goal of
improving radiotherapy of HNSCC. The CCG has a core
project (Figure 3) which starts with the molecular char-
acterisation of clinical samples from selected HNSCC
cohorts. With regard to the global characterisation of
molecular levels we focus on the genome andmiRNA level
in the first place since these are the best accessible ones
wenn it comes to analysis of archived clinical samples. The
global molecular characterisation data are complemented
with typing of the HPV status and individual mutations
known to have an impact in HNSCC, with clinical follow-
up including endpoints reflecting response of the treated
tumours to radiation therapy. These are integrated in
order to come to candidate molecules that are likely to
be involved in the molecular mechanisms of radiation
sensitivity and that can serve as a starting point for time-
resolved molecular characterisation at the transcriptome
and miRNA level of cell culture models after perturbation
by regulating the candidate molecules that were identified
in the clinical samples. The resulting global time-course




Genomic copy number profiling HPV status typing
miRNA profiling Genetic analysis and characterisation of radiosensitivity
Cell culture models
- HNSCC cell culture models
- perturbation experiments
- network reconstruction
- modelling of radiation-response
Integrative analysis
- integration of multi-level molecular data
- correlation with clinical data
- determination of radiosensitivity
Identification of candidate markers and 
targets
Radiosensitisation
- radiosensitisation of cell culture models with 
targeted agents
- characterisation of radiosensitivity
Figure 3 Strategy of the clinical cooperation group “Personalized Radiotherapy in Head and Neck Cancer” implementing systems
biology approaches.
mRNA and miRNA data are then used for reconstructing
the interaction networks of the candidate molecules and
also allow to infer the molecular mechanisms associated
with radiation sensitivity. Different methods are explored
and those with the best performance, which will be vali-
dated by further experiments (i.e. knock-down of specific
genes), will be chosen. Since we are looking at gene regula-
tory networks that are specifically influenced by genomic
copy number and miRNA expression the use of Gaussian
graphical modelling [23] might provide the solution here.
Further, using graph network analysis the most important
(central) nodes that could be used as molecular modula-
tors of radiation sensitivity are identified. The selection of
candidates will be performed using well established cen-
trality measures (e.g. betweenness) in order to get to the
“most important” molecules of the network. In a second
step this selection will be explored for drug “targetabil-
ity” using established drug databases such as DrugBank
[51]. These candidates are then characterised for their
radiation sensitivity modulating effect in cell culture mod-
els. By following this approach, with integrative systems
biology as a central element, we will identify potentially
important molecular targets being used for a more effi-
cient radiation therapy resulting in lower rate of tumour
recurrence and overall better long-time survival of the
patients.
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Limitations of systems biology in radiation
oncology research
In radiation oncology research one has to deal with the
effects of radiation on cells whilst the main aim is to pro-
tect and favour the tissue surrounding a tumour and to
harm and delimit the tumour itself as much as possible.
Radiation effects are composed of deterministic effects
such as cell death or normal tissue reactions and stochas-
tic effects such as point mutations or structural changes
or changes in copy number of genes. Whilst for determin-
istic effects it is possible to predict what effects at which
amounts are expected when applying a certain dose of
defined radiation quality it is, by definition, impossible to
predict the stochastic effects. Although there are systems
biology approaches dealing with stochastic effects they
cannot predict the occurrence of the primary radiation
damage which in the radiation therapy setting are dam-
ages at the DNA level. So it remains unpredictable which
genes are going be to altered as a cause of radiation treat-
ment in the cell populations of both, the tumour tissue
and its surrounding normal tissue, surviving each fraction
in fractionated radiation therapy. Logically, the molecular
mechanisms associated with the radiation-induced gene
alterations cannot be predicted either. Thus, one could
doubt the use of systems approaches in radiation oncol-
ogy research at all. However, major obstacles of successful
radiotherapy such local tumour recurrence or radiation
resistance seem to be ruled by a set of common molec-
ular mechanisms. For that reason it should be legitimate
to assume that the primary effects of radiation indeed are
of stochastic nature but that the inter-individual selec-
tive pressures effectuated by the radiation therapy and
any concomitant treatment are the same between indi-
viduals and therefore lead to manifestation of the same
set of molecular survival strategies. At this stage the sys-
tem becomes describable and predictable again. So the
prerequisites of successful systems approaches in radia-
tion oncology research are to mimic the in vivo situation
as best as possible and to “reverse translate” the findings
gained in cell culture models to clinical samples HNSCC
patients.
Conclusions
In the context of radiation therapy and the improve-
ment of this therapy option alone or in combination with
immuno- or chemotherapy seems to be extremely impor-
tant taking into account its wide usage and the relatively
low success rate with regard to long-term survival. The
key feature to be addressed for improving radiation ther-
apy is radiation sensitivity and its modulation towards
higher sensitivity of tumour cells and lower sensitivity of
the surrounding normal cells. Conventional approaches
seeking for potential modulators did not yet provide the
breakthrough, therefore implementing systems biology
methodology into radiation oncology research is a very
much promising approach. The clinical cooperation group
“CCG Personalized Radiotherapy in Head and Neck
Cancer” between the Research Unit of Radiation Cyto-
genetics at the Helmholtz-Zentrum München and the
Radiation Oncology Clinics of the Ludwig-Maximilians
Universität München currently applies a systems biology
approach in order to identify candidate radiation sensitiv-
ity modulators for improved radiation therapy of HNSCC.
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